Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (4): 680-685. doi: 10.19723/j.issn.1671-167X.2021.04.010

Previous Articles     Next Articles

Renal functional compensation after unilateral radical nephrectomy of renal cell carcinoma

HAN Song-chen,HUANG Zi-xiong,LIU Hui-xin,XU Tao   

  1. Department of Urology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2021-03-14 Online:2021-08-18 Published:2021-08-25
  • Contact: Tao XU

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate factors influencing renal functional compensation(RFC) of the preserved kidney after radical nephrectomy (RN). Methods: A total of 286 patients treated with RN in Peking University People’s Hospital were retrospectively analyzed. Preoperative body mass index (BMI), systolic blood pressure (SBP), history of smoking, history of chronic diseases and other basic information, as well as preoperative blood biochemistry, urine routine, imaging examination results were recorded. All the patients underwent 99mtechnetium-diethylenetriamine pentaacetic acid (99mTc-DTPA) renal scans before operation. The surgical method, pathology and blood creatinine values from 1 month to 60 months after RN were recorded. Preoperative and postoperative estimated glomerular filtration rate (eGFR) was calculated by the chronic kidney disease epidemiology collaboration (CKD-EPI) formula. Renal functional compensation was defined as percent change in eGFR of the preserved kidney after RN compared with the preoperative eGFR. Univariate and multivariate regression analyses were used to identify predictive factors of RFC. Results: Median age was 61 years and 65.4% of the patients were male. Early stage (T1 or T2) tumors were found in 83.6% of the cases. 18.5% of the patients had preoperative diabetes mellitus, 39.5% had hypertension, 19.2% had a history of smoking, and 27.6% were found to have renal cyst on the contralateral side. In the study, 226 cases underwent laparoscopic radical nephrectomy and 60 cases underwent open radical nephrectomy. Renal clear cell carcinoma was the most common pathological type, accounting for 88.5%. The median tumor maximum diameter was 4.5 cm (0.7-13.5 cm). Median renal function compensation was 27% one month after radical nephrectomy. Functional stability was then observed to 5 years. The results of univariate analysis showed that age, gender, preoperative blood uric acid, preoperative urine protein, contralateral renal cyst, and percentage of split renal function of contralateral kidney were correlated with RFC (P<0.05). Among them, UA level and split renal function of contralateral kidney were strongly negatively correlated with RFC. The results of multivariate linear regression analysis showed age (P<0.001), blood uric acid (P<0.001), urine protein (P=0.002), preoperative eGFR (P<0.001) and the split renal function of contralateral kidney (P<0.001) were independent predictors of RFC. Conclusion: The basic examinations, such as blood biochemistry, urine routine and renal scan before RN are of great significance in predicting the compen-satory ability of the preserved kidney after RN, which is supposed to be taken into consideration when making clinical decision.

Key words: Renal cell carcinoma, Radical nephrectomy, 99mTc-DTPA renal dynamic imaging, Renal functional compensation

CLC Number: 

  • R737.11

Table 1

Preoperative patient characteristics"

Items Data
Age/years, M (range) 61 (22-85)
Gender, n(%)
Male 187 (65.4)
Femal 99 (34.6)
BMI/(kg/m2), M (range) 24.91 (16.59-41.97)
SBP/mmHg, M (range) 131 (86-188)
Concomitant diabetes mellitus, n(%)
Yes 53 (18.5)
No 233 (81.5)
Concomitant hypertension, n(%)
Yes 113 (39.5)
No 173 (60.5)
Smoking status, n(%)
Current or former 74 (25.9)
Never 212 (74.1)
Alcohol intaking, n(%)
Current or former 55 (19.2)
Never 231 (80.8)
Glucose/(mmol/L), M (range) 5.35 (3.49-13.45)
BUN/(mmol/L), M (range) 5.00 (2.58-16.52)
Scr/((mol/L), M (range) 73 (38-315)
UA/((mol/L), M (range) 329 (107-655)
eGFR [mL/(min·1.73 m2), M (range) 92.35 (17.16-141.88)
SG, M (range) 1.015 (1.000-1.040)
Preoperative proteinuria, n(%)
Positive 37 (12.9)
Negtive 249 (87.1)
Renal cyst of contraleteral side, n(%)
≥1 79 (27.6)
0 207 (72.4)
Renal cyst of affected side, n(%)
≥1 82 (28.7)
0 204 (71.3)
Maximum diameter of tumors/cm, M (range) 4.5 (0.7-13.5)
Histology, n(%)
Clear cell 253 (88.5)
Papillary 6 (2.1)
Chromophobe 9 (3.1)
Others 18 (6.3)
T stage, n(%)
T1 227 (79.4)
T2 12 (4.2)
T3 46 (16.1)
T4 1 (0.3)
Nephrectomy, n(%)
Laparoscopic 226 (79.0)
Open 60 (21.0)

Figure 1

Bland-Altman plot of preoperative eGFR and rGFR SD, standard deviation; eGFR, estimated glomerular filtration rate; rGFR, reference glomerular filtration rate."

Table 2

Preoperative and postoperative renal function measurements"

Items Data
Preoperative
CKD stage, n(%)
Grade 1: eGFR≥90 mL/(min·1.73 m2) 165 (57.7)
Grade 2: eGFR 60-89 mL/(min·1.73 m2) 101 (35.3)
Grade 3: eGFR 30-59 mL/(min·1.73 m2) 18 (6.3)
Grade 4: eGFR 15-29 mL/(min·1.73 m2) 2 (0.7)
eGFR/[mL/(min·1.73 m2)], M (range)
Global 92.3 (17.2-141.9)
Contraleteral kidney 46.6 (9.41-93.3)
Affected kidney 44.9 (7.7-74.0)
rGFR/[mL/(min·1.73 m2)], M (range)
Global 91.2 (24.8-185.30)
Contraleteral kidney 47.4 (14.2-88.7)
Affected kidney 45.2 (8.8-103.5)
Split renal function/%, M (range)
Contraleteral kidney 51 (26-83)
Affected kidney 49 (17-74)
Postoperateve
eGFR/[mL/(min·1.73 m2)], M (range)
1 months 64.1 (15.0-107.0)
3-12 months 63.3 (17.4-123.1)
18-36 months 63.2 (6.3-119.3)
48-60 months 66.6 (6.0-118.0)
RFC/%, M (range)
1 months 27 (-25-67)
3-12 months 28 (-36-69)
24-36 months 26 (-54-60)
48-60 months 26 (-56-70)

Table 3

Predictors of percent renal functional compensation after radical nephrectomy"

Items Univariable Multivariable
Coefficient P value Coefficient Standard error Standardized coefficient P value
Age -0.004 0.042 -0.009 0.002 -0.313 <0.001
Gender (Male vs. Female) 0.129 0.004 0.070 0.043 0.094 0.099
BMI -0.004 0.519 0.001 0.005 0.014 0.794
Smoking (Yes vs. No) 0.001 0.977 0.005 0.044 0.006 0.914
Hypertension (Yes vs. No) -0.017 0.704 -0.003 0.039 -0.004 0.937
Diabetes mellitus (Yes vs. No) -0.087 0.112 -0.053 0.048 -0.058 0.266
Preoperative UA -0.001 <0.001 -0.001 0.218×10-3 -0.305 <0.001
Preoperative proteinuria (Yes vs. No) -0.145 0.021 -0.093 0.029 0.157 0.002
Renal cyst of contraleteral side (Yes vs. No) -0.114 0.016 -0.075 0.040 -0.094 0.060
Preoperative eGFR -0.001 0.210 -0.008 0.001 -0.420 <0.001
Split renal function of contraleteral kidney -1.878 <0.001 -2.092 0.250 -0.424 <0.001

Figure 2

Correlation between the renal functional compensation and preoperative renal function as well as split renal function"

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(1):7-30.
doi: 10.3322/caac.v70.1
[2] Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline [J]. J Urol, 2017, 198(3):520-529.
doi: S0022-5347(17)59870-5 pmid: 28479239
[3] Patel N, Mason P, Rushton S, et al. Renal function and cardiovascular outcomes after living donor nephrectomy in the UK: Qua-lity and safety revisited [J]. BJU Int, 2013, 112(2):134-142.
[4] Lee SH, Kim DS, Cho S, et al. Comparison of postoperative estimated glomerular filtration rate between kidney donors and radical nephrectomy patients, and risk factors for postoperative chronic kidney disease [J]. Int J Urol, 2015, 22(7):674-678.
doi: 10.1111/iju.2015.22.issue-7
[5] Srivastava T, Hariharan S, Alon US, et al. Hyperfiltration-mediated injury in the remaining kidney of a transplant donor [J]. Transplantation, 2018, 102(10):1624-1635.
doi: 10.1097/TP.0000000000002304 pmid: 29847501
[6] Aguilar Palacios D, Caraballo ER, Tanaka H, et al. Compensatory changes in parenchymal mass and function after radical nephrectomy [J]. J Urol, 2020, 204(1):42-49.
doi: 10.1097/JU.0000000000000797 pmid: 32073996
[7] Zabor EC, Furberg H, Lee B, et al. Long-term renal function recovery following radical nephrectomy for kidney cancer: Results from a multicenter confirmatory study [J]. J Urol, 2018, 199(4):921-926.
doi: 10.1016/j.juro.2017.10.027
[8] Kawamura N, Yokoyama M, Fujii Y, et al. Recovery of renal function after radical nephrectomy and risk factors for postoperative severe renal impairment: A Japanese multicenter longitudinal study [J]. Int J Urol, 2016, 23(3):219-223.
doi: 10.1111/iju.13028 pmid: 26663437
[9] Park BH, Sung HH, Jeong BC, et al. Tumor size is associated with compensatory hypertrophy in the contralateral kidney after radical nephrectomy in patients with renal cell carcinoma [J]. Int Urol Nephrol, 2016, 48(6):977-983.
doi: 10.1007/s11255-016-1250-y
[10] Anderson RG, Bueschen AJ, Lloyd LK, et al. Short-term and long-term changes in renal function after donor nephrectomy [J]. J Urol, 1991, 145(1):11-13.
doi: 10.1016/S0022-5347(17)38232-0
[11] Okada T, Omoto-Kitao M, Mukamoto M, et al. Compensatory renal growth in uninephrectomized immature rats: Proliferative acti-vity and epidermal growth factor [J]. J Vet Med Sci, 2010, 72(8):975-980.
doi: 10.1292/jvms.09-0496
[12] Shehab AB, Shaheen FA, Fallatah A, et al. Early changes in vo-lume and function of the remaining kidney after unilateral donor nephrectomy [J]. Saudi J Kidney Dis Transpl, 1994, 5(4):474-478.
pmid: 18583774
[13] Vergho D, Burger M, Schrammel M, et al. Matched-pair analysis of renal function in the immediate postoperative period: A comparison of living kidney donors versus patients nephrectomized for renal cell cancer [J]. World J Urol, 2015, 33(5):725-731.
doi: 10.1007/s00345-014-1423-1
[14] Scosyrev E, Messing EM, Sylvester R, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: Results from EORTC randomized trial 30904 [J]. Eur Urol, 2014, 65(2):372-377.
doi: 10.1016/j.eururo.2013.06.044 pmid: 23850254
[15] Sarkar D, Agrawal A, Agrawal DK. Clinical assessment of stabilisation of renal function after nephrectomy [J/OL]. Urologia, 2021. .
[16] Takagi T, Mir MC, Sharma N, et al. Compensatory hypertrophy after partial and radical nephrectomy in adults [J]. J Urol, 2014, 192(6):1612-1618.
doi: 10.1016/j.juro.2014.06.018
[17] Jeon HG, Choo SH, Jeong BC, et al. Uric acid levels correlate with baseline renal function and high levels are a potent risk factor for postoperative chronic kidney disease in patients with renal cell carcinoma [J]. J Urol, 2013, 189(4):1249-1254.
doi: 10.1016/j.juro.2012.11.043
[18] Cho A, Lee JE, Jang HR, et al. Association between pre-donation serum uric acid concentration and change in renal function after living kidney donation in women [J]. Intern Med J, 2014, 44(12a):1217-1222.
doi: 10.1111/imj.12591 pmid: 25266773
[19] Yim K, Bindayi A, Mckay R, et al. Rising serum uric acid level is negatively associated with survival in renal cell carcinoma [J]. Cancers (Basel), 2019, 11(4):536.
doi: 10.3390/cancers11040536
[20] Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction [J]. Kidney Int, 2005, 67(5):1739-1742.
pmid: 15840020
[21] Guo B, Guo Y, Liu C. Predictive factors of progression in renal function after unilateral nephrectomy in renal malignancy [J]. J buon, 2020, 25(3):1650-1657.
[22] Zhang Z, Zhao J, Zabell J, et al. Proteinuria in patients undergoing renal cancer surgery: Impact on overall survival and stability of renal function [J]. Eur Urol Focus, 2016, 2(6):616-622.
[23] 杜晓英, 李林法, 何强, 等. 99mTc-DTPA肾动态显像检测肾小球滤过率的临床应用评价 [J]. 中华肾脏病杂志, 2006, 22(5):266-270.
[1] Fan SHU, Liyuan GE, Hanzhang DENG, Haoming YIN, Junyong OU, Shaohui DENG, Yichang HAO, Min LU, Zhanyi ZHANG, Peichen DUAN, Shudong ZHANG. Molecular characteristics for poor prognosis related renal cell carcinoma with lymph metastases [J]. Journal of Peking University (Health Sciences), 2026, 58(3): 631-640.
[2] Haoming YIN, Zijie WANG, Fan SHU, Zhanyi ZHANG, Hui LIANG, Shudong ZHANG. Expression and significance of the FABP6 long transcript in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 393-398.
[3] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[4] Zhanyi ZHANG, Min LU, Yuehao SUN, Jinghan DONG, Xiaofei HOU, Chunlei XIAO, Guoliang WANG, Xiaojun TIAN, Lulin MA, Hongxian ZHANG, Shudong ZHANG. Clinicopathological features and survival analysis of TFE3-rearranged renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 650-661.
[5] Zezhen ZHOU, Liyuan GE, Fan ZHANG, Shaohui DENG, Ye YAN, Hongxian ZHANG, Guoliang WANG, Lei LIU, Yi HUANG, Shudong ZHANG. A retrospective matching study of partial nephrectomy and radical nephrectomy for pathological T3a stage renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 704-710.
[6] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[7] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[8] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[9] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
[10] Yun-yi XU,Zheng-zheng SU,Lin-mao ZHENG,Meng-ni ZHANG,Jun-ya TAN,Ya-lan YANG,Meng-xin ZHANG,Miao XU,Ni CHEN,Xue-qin CHEN,Qiao ZHOU. Read-through circular RNA rt-circ-HS promotes hypoxia inducible factor 1α expression and renal carcinoma cell proliferation, migration and invasiveness [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 217-227.
[11] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[12] Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155.
[13] Cai-peng QIN,Yu-xuan SONG,Meng-ting DING,Fei WANG,Jia-xing LIN,Wen-bo YANG,Yi-qing DU,Qing LI,Shi-jun LIU,Tao XU. Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 663-668.
[14] Mei-ni ZUO,Yi-qing DU,Lu-ping YU,Xiang DAI,Tao XU. Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 636-643.
[15] Tian-yu CAI,Zhen-peng ZHU,Chun-ru XU,Xing JI,Tong-de LV,Zhen-ke GUO,Jian LIN. Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 628-635.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd